Original research
by
Lillie, Kate M. et al
Release Date
2021
Geography
USA
Language of Resource
English
Full Text Available
No
Open Access / OK to Reproduce
No
Peer Reviewed
Yes
Objective
The objective of this study was to identify variables associated with buprenorphine/naloxone retention among Alaska Native and American Indian people with opioid use disorder
Findings/Key points
We found that 63% of the 240 patients were retained in buprenorphine/naloxone treatment at 90 days, 51% at 6 months, and 40% at 1 year, slightly lower than the general US population. Younger patients and those with co-occurring substance use remain at higher risk of discontinuing buprenorphine/naloxone treatment for OUD in this population of ANAI people. Our study highlights the need to address poly-substance use among ANAI people in treatment.
Design/methods
The sample was 240 ANAI adults in Anchorage, Alaska who received buprenorphine/naloxone treatment for an OUD
Keywords
Equity
About PWUD
Outcomes
Illegal drugs
Indigenous
Substitution/OAT
